Revista española de cardiología (English ed.)最新文献_第10页

OCT-guided versus IVUS-guided percutaneous coronary intervention in patients with acute myocardial infarction. Do we have a winner? 急性心肌梗死患者经皮冠状动脉介入治疗中OCT引导与IVUS引导的对比。我们有赢家吗？

IF 7.2 2区医学

Revista española de cardiología (English ed.) Pub Date : 2024-08-01 DOI: 10.1016/j.rec.2024.02.002

引用次数: 0

2024 SIAC guidelines on cardiorespiratory rehabilitation in pediatric patients with congenital heart disease 2024 SIAC 儿童先天性心脏病患者心肺康复指南。

IF 7.2 2区医学

Revista española de cardiología (English ed.) Pub Date : 2024-08-01 DOI: 10.1016/j.rec.2024.05.001

{"title":"2024 SIAC guidelines on cardiorespiratory rehabilitation in pediatric patients with congenital heart disease","authors":"","doi":"10.1016/j.rec.2024.05.001","DOIUrl":"10.1016/j.rec.2024.05.001","url":null,"abstract":"<div><p>The 2024 Interamerican Society of Cardiology (SIAC) guidelines on cardiorespiratory rehabilitation (CRR) in pediatric patients with congenital heart disease aim to gather and evaluate all relevant evidence available on the topic to unify criteria and promote the implementation of CRR programs in this population in Latin America and other parts of the world. Currently, there is no unified CRR model for the pediatric population. Consequently, our goal was to create these CRR guidelines adapted to the characteristics of congenital heart disease and the physiology of this population, as well as to the realities of Latin America. These guidelines are designed to serve as a support for health care workers involved in the care of this patient group who wish to implement a CRR program in their workplace. The guidelines include an easily reproducible program model that can be implemented in any center. The members of this Task Force were selected by the SIAC on behalf of health care workers dedicated to the care of pediatric patients with congenital heart disease. To draft the document, the selected experts performed a thorough review of the published evidence.</p></div>","PeriodicalId":38430,"journal":{"name":"Revista española de cardiología (English ed.)","volume":"77 8","pages":"Pages 680-689"},"PeriodicalIF":7.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio in cardiac amyloidosis 心脏淀粉样变性患者三尖瓣环面收缩期偏移/收缩期肺动脉压力比值的预后价值。

IF 7.2 2区医学

Revista española de cardiología (English ed.) Pub Date : 2024-08-01 DOI: 10.1016/j.rec.2024.01.001

{"title":"Prognostic value of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio in cardiac amyloidosis","authors":"","doi":"10.1016/j.rec.2024.01.001","DOIUrl":"10.1016/j.rec.2024.01.001","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>The tricuspid annular plane systolic excursion/systolic pulmonary artery pressure (TAPSE/SPAP) ratio is a noninvasive surrogate of right ventricular to pulmonary circulation that has prognostic implications in patients with heart failure (HF) or pulmonary hypertension. Our purpose was to evaluate the prognostic value of the TAPSE/SPAP ratio in patients with cardiac amyloidosis.</p></div><div><h3>Methods</h3><p>We used the database of the AMIGAL study, a prospective, observational registry of patients with cardiac amyloidosis recruited in 7 hospitals of the Autonomous Community of Galicia, Spain, from January 1, 2018 to October 31, 2022. We selected patients whose baseline TAPSE/SPAP ratio was calculated with transthoracic echocardiography. Long-term survival and survival free of HF hospitalization were assessed by means of 5 different multivariable Cox regression models. Median follow-up was 680 days.</p></div><div><h3>Results</h3><p>We studied 233 patients with cardiac amyloidosis, among whom 209 (89.7%) had transthyretin type. The baseline TAPSE/SPAP ratio correlated significantly with clinical outcomes. Depending on the multivariable model considered, the adjusted hazard ratios estimated per 0.1mm/mmHg increase of baseline TAPSE/SPAP ratio ranged from 0.76 to 0.84 for all-cause mortality. Similarly, the ratios for all-cause mortality of HF hospitalization ranged from 0.79 to 0.84. The addition of the baseline TAPSE/SPAP ratio to the predictive model of the United Kingdom National Amyloidosis Centre resulted in an increase in Harrell's c-statistic from 0.662 to 0.705 for all-cause mortality and from 0.668 to 0.707 for all-cause mortality or HF hospitalization.</p></div><div><h3>Conclusions</h3><p>Reduced TAPSE/SPAP ratio is an independent adverse prognostic marker in patients with cardiac amyloidosis.</p></div>","PeriodicalId":38430,"journal":{"name":"Revista española de cardiología (English ed.)","volume":"77 8","pages":"Pages 634-644"},"PeriodicalIF":7.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving the quality of healthcare. Results of the SEC-Excelente accreditation program in heart failure of the Spanish Society of Cardiology 提高医疗质量。西班牙心脏病学会心力衰竭 SEC-Excelente 认证计划的结果。

IF 7.2 2区医学

Revista española de cardiología (English ed.) Pub Date : 2024-08-01 DOI: 10.1016/j.rec.2024.02.015

引用次数: 0

Primary mitral regurgitation treated with transcatheter edge-to-edge repair. Does transthoracic echocardiography provide prognostic information? 经导管边缘对边缘修补术治疗原发性二尖瓣反流。经胸超声心动图能否提供预后信息？

IF 7.2 2区医学

Revista española de cardiología (English ed.) Pub Date : 2024-08-01 DOI: 10.1016/j.rec.2024.02.016

引用次数: 0

Novel stroke prevention strategies following catheter ablation for atrial fibrillation 心房颤动导管消融术后预防中风的新策略。

IF 7.2 2区医学

Revista española de cardiología (English ed.) Pub Date : 2024-08-01 DOI: 10.1016/j.rec.2024.02.008

引用次数: 0

Familial clustering of coronary anomalies identified through the RAC sign 通过 RAC 标志发现冠状动脉异常的家族聚集。

IF 7.2 2区医学

Revista española de cardiología (English ed.) Pub Date : 2024-08-01 DOI: 10.1016/j.rec.2023.12.017

引用次数: 0

Periprocedural use of antithrombotic therapy in interventional cardiology in Spain: are we doing better than other specialties? 西班牙介入心脏病学的围手术期抗血栓治疗：我们比其他专科做得更好吗？

IF 7.2 2区医学

Revista española de cardiología (English ed.) Pub Date : 2024-08-01 DOI: 10.1016/j.rec.2024.02.017

引用次数: 0

Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study. 射血分数保留型心力衰竭患者转甲状腺素心脏淀粉样变性的患病率：PRACTICA 研究。

IF 7.2 2区医学

Revista española de cardiología (English ed.) Pub Date : 2024-07-31 DOI: 10.1016/j.rec.2024.07.005

Pablo García-Pavía, José Manuel García-Pinilla, Ainara Lozano-Bahamonde, Sergi Yun, Antonio García-Quintana, Juan José Gavira-Gómez, Miguel Ángel Aibar-Arregui, Gonzalo Barge-Caballero, Julio Núñez Villota, Laura Bernal, Patricia Tarilonte

{"title":"Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.","authors":"Pablo García-Pavía, José Manuel García-Pinilla, Ainara Lozano-Bahamonde, Sergi Yun, Antonio García-Quintana, Juan José Gavira-Gómez, Miguel Ángel Aibar-Arregui, Gonzalo Barge-Caballero, Julio Núñez Villota, Laura Bernal, Patricia Tarilonte","doi":"10.1016/j.rec.2024.07.005","DOIUrl":"10.1016/j.rec.2024.07.005","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Transthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure with preserved ejection fraction (HFpEF). This study sought to determine the prevalence of ATTR-CA among HFpEF patients in a multicenter nationwide study.</p><p><strong>Methods: </strong>Consecutive ambulatory or hospitalized patients aged ≥ 50 years with HFpEF and left ventricle hypertrophy ≥ 12mm were studied at 20 Spanish hospitals. Screening for cardiac amyloidosis was initiated according to the usual clinical practice of each center. Positive scintigraphs were centrally analyzed.</p><p><strong>Results: </strong>422 patients were included, of whom 387 underwent further screening for cardiac amyloidosis. A total of 65 patients (16.8%) were diagnosed with ATTR-CA, none below 75 years. There was an increase of prevalence with age. Of them, 60% were male, with a mean age of 85.3±5.2 years, mean left ventricle ejection fraction of 60.3±7.6% and a mean maximum left ventricle wall thickness of 17.2 [12-25] mm. Most of the patients were New York Heart Association class II (48.4%) or III (46.8%). Besides being older than non-ATTR-CA patients, ATTR-CA patients had higher median NT-proBNP levels (3801 [2266-7132] vs 2391 [1141-4796] pg/mL; P=.003). There was no statistical difference in the prevalence of ATTR-CA by sex (19.7% for men and 13.8% for women, P=.085). A ∼7% (4/56) of the patients exhibited a genetic variant (ATTRv).</p><p><strong>Conclusions: </strong>This multicenter nationwide study found a prevalence of 16.8%, confirming that ATTR-CA is a significant contributor to HFpEF in male and female patients with left ventricle hypertrophy and more than 75 years.</p>","PeriodicalId":38430,"journal":{"name":"Revista española de cardiología (English ed.)","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transapical transcatheter mitral valve replacement for mitral valve disease: an Iberian experience. 经心尖经导管二尖瓣置换术治疗二尖瓣疾病：伊比利亚的经验。

IF 7.2 2区医学

Revista española de cardiología (English ed.) Pub Date : 2024-07-26 DOI: 10.1016/j.rec.2024.07.004

Eva Gutiérrez-Ortiz, Javier Cobiella, Christian Muñoz-Guijosa, Rui C Teles, Rodrigo Estévez-Loureiro, Vanessa Moñivas, Ander Regueiro, Sara Blasco-Turrión, Patricia Mahía, Danela Figuereo Beltre, Pedro Freitas, Miguel Piñón, Ignacio J Amat-Santos, Ignasi Julià Amill, Tiago Nolasco, Daniel Pereda, Carlos Martín López, Luis Nombela-Franco

{"title":"Transapical transcatheter mitral valve replacement for mitral valve disease: an Iberian experience.","authors":"Eva Gutiérrez-Ortiz, Javier Cobiella, Christian Muñoz-Guijosa, Rui C Teles, Rodrigo Estévez-Loureiro, Vanessa Moñivas, Ander Regueiro, Sara Blasco-Turrión, Patricia Mahía, Danela Figuereo Beltre, Pedro Freitas, Miguel Piñón, Ignacio J Amat-Santos, Ignasi Julià Amill, Tiago Nolasco, Daniel Pereda, Carlos Martín López, Luis Nombela-Franco","doi":"10.1016/j.rec.2024.07.004","DOIUrl":"10.1016/j.rec.2024.07.004","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Transcatheter mitral valve replacement (TMVR) is an emerging treatment alternative for mitral valve (MV) disease in patients who were ineligible for surgical intervention or edge-to-edge repair. This study aimed to assess the short- and mid-term outcomes of this procedure.</p><p><strong>Methods: </strong>We conducted a prospective registry to include the initial experience with symptomatic, consecutive patients who underwent TMVR using the transapical Tendyne system at 7 centers in the Iberian Peninsula. Baseline clinical and imaging data, periprocedural information, and follow-up assessments were collected at 1 month and 1 year.</p><p><strong>Results: </strong>A total of 40 patients (mean age 78.5 years [76-82], 47,5% males) underwent TMVR. The majority had significant surgical risk, comorbidities, and advanced functional class. All patients had significant mitral regurgitation (MR), except for 2 with severe stenosis. Previous MV intervention and off-label indication for the procedure were present in 4 (10.0%) and 8 (20.0%) patients, respectively. Technical success was recorded in 100%, device success in 95.0%, and procedural success in 85.0% at 30-day. All-cause mortality was 2.5% and 17.5% at the 1-month and 1-year follow-up, respectively. MR reduction (≤ 1) and functional class improvement (NYHA I-II) were observed at 1 year in 93.9% and 87.9% of survivors, respectively.</p><p><strong>Conclusions: </strong>Treatment with TMVR produced enduring resolution of MV disease and notable functional enhancement at 1 year of follow-up. The procedure demonstrated a satisfactory early safety profile, although 1-year mortality remained relatively high in this high-risk population.</p>","PeriodicalId":38430,"journal":{"name":"Revista española de cardiología (English ed.)","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0